-
FDA grants accelerated approval to Zykadia
SILVER SPRING, Md. — The Food and Drug Administration on Tuesday granted approval to Zykadia (ceritinib) for patients with a specific type of late-stage (metastatic) non-small cell lung cancer (NSCLC).
The drug — an anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor — blocks proteins that promote the development of cancerous cells and is intended for patients with metastatic ALK-positive NSCLC who were previously treated with crizotinib.